Low total cholesterol levels are linked to a higher risk of death among people with idiopathic pulmonary fibrosis, a new study from China with more than three years of follow-up data found. “We conducted a long-term follow-up study in patients with IPF and observed that lower [total cholesterol] levels…
News
An imbalance in gene activity within two types of immune cells explains why idiopathic pulmonary fibrosis (IPF) progresses but in people who develop lung fibrosis after a severe COVID-19 infection, their lungs get better, a new study finds. Researchers showed mortality risk in IPF and COVID-19 was tied to…
Mediar Therapeutics is planning to launch a Phase 2 clinical trial to test its experimental therapy MTX-463 in people with idiopathic pulmonary fibrosis (IPF). The company has entered into a global licensing agreement with Eli Lilly to advance the development of MTX-463. Mediar will be responsible for…
Broadway performers will sing show tunes at the 15th annual Pulmonary Fibrosis Foundation Broadway Belts for PFF! event, which will be held at New York’s Sony Hall March 10 to raise funds and awareness for pulmonary fibrosis, a disease in which scar tissue forms in the lungs. Tony…
Inhibiting the HIF2 protein — fully, hypoxia-inducible factor 2 — was found to ease scarring in a mouse model of lung injury and could be a promising therapeutic strategy for treating idiopathic pulmonary fibrosis (IPF), according to the results of new preclinical research. In the lab, a team of…
Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study identifying the enzyme as a potential therapeutic target for the condition. Experiments showed that FASN was elevated in lung scar…
The investigational therapy LYT-100 (deupirfenidone) significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), outperforming the standard of care therapy Esbriet. PureTech Health’s treatment candidate also caused fewer gastrointestinal side effects in patients. That’s according to top-line data from the ongoing Phase…
Trevi Therapeutics announced that its ongoing Phase 2b clinical trial testing Haduvio (nalbuphine extended-release tablets) in people with idiopathic pulmonary fibrosis (IPF) who have chronic cough has reached 75% of its targeted patient enrollment. The Phase 2b CORAL trial (NCT05964335) is still seeking to recruit a…
The first patient has been dosed in a Phase 2b clinical trial of Endeavor Biomedicines’ investigational oral therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF). WHISTLE-PF (NCT06422884) seeks to enroll around 200 adults in 14 countries. The first patient was dosed in Australia. The study’s launch…
The Pulmonary Fibrosis Foundation (PFF) has launched “PF Basics: Info for Newly Diagnosed Patients,” a new educational program to help patients with pulmonary fibrosis (PF) and interstitial lung disease get answers to the most pressing questions about their disease after a recent diagnosis. “We heard from patients and caregivers…
